PharmCAD and Kynogen sign a joint development agreement for new anticancer drugs

On January 22 , 2021 PharmCAD, an artificial intelligence ( AI )-based new drug development company, reported that it signed a joint development agreement with Kainogen to develop and commercialize a new anticancer drug (Press release, PharmCADD, JAN 22, 2021, View Source [SID1234644206]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

With this contract, PharmCAD plans to use the new drug development platform ‘Pharmulator’ to discover anticancer drug candidates optimized for Kainogen’s target proteins within 20 weeks and provide them to Kainogen. Kainogen will synthesize substances and conduct clinical trials.

Pharmulator is a new drug development platform that combines AI , physics, chemistry, and bioinformatics. It consists of modules for protein 3D structure prediction, molecular dynamics simulation, quantum calculation, toxicity prediction, and new drug creation. Through the combination of these modules, candidate substances with a high probability of success as a new drug can be derived.

Kainogen is a company developing a next-generation anti-cancer technology platform based on immunosynapse and immunometabolism technologies that strengthen the bond between cancer cells and immune cells.

Kainogen CEO Moon Ji-young said, "Through the joint development agreement, we will be able to further accelerate the speed of research and development of not only the immune anti-cancer drug pipeline that we are pursuing, but also the metabolic anti-cancer drug pipeline."

Taehyung Kwon, CEO of PharmCAD, said, "Through the joint development agreement with Kainogen, which is focusing on developing next-generation anticancer technology, we will be able to further strengthen the technological scalability and reliability of PharmCAD’s new drug development platform ‘Pamulator.’"